Common Questions & Myths

Combined estrogen-progestogen MHT is associated with a small increase in breast cancer risk, though the absolute risk for a woman in her early 50s is small — similar to lifestyle risks like alcohol or obesity. Estrogen-only MHT (for women without a uterus) does not increase breast cancer risk. The type of progestogen may matter, with micronized progesterone carrying a lower risk than synthetic progestins. Breast cancer history is a contraindication to systemic MHT. Your individual risk should be discussed with your doctor.

Not the way it used to. In November 2025, the U.S. Food and Drug Administration began removing the broad boxed warnings about cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy products. Those warnings dated from early interpretations of the Women’s Health Initiative and had discouraged many women from considering treatment. The boxed warning about endometrial cancer remains for systemic estrogen-alone products, which is why women who still have a uterus take a progestogen with estrogen. The updated labeling recommends starting systemic hormone therapy within 10 years of menopause or before age 60. The change does not mean MHT is right for everyone: your own history, risks and preferences still matter.

No. This advice is outdated. There is no mandated maximum duration. Duration should be based on ongoing benefits, risks, and your preferences. Many guidelines now support continued use beyond 5 years in appropriate women.

Not necessarily. The word “bioidentical” describes the chemical structure, not the safety profile. Many standard regulated MHT preparations ARE body-identical (including estradiol and micronized progesterone). Compounded bioidentical preparations are not recommended because they lack standardized dosing, purity assurance, and safety data.

Starting MHT after age 60–65 requires more careful assessment. The cardiovascular risk picture is less favorable in older women, and the “timing hypothesis” suggests protective effects are greatest when started close to menopause. Specialist review is recommended. However, local vaginal estrogen can be started at any age with minimal systemic effects.

On balance, MHT does not cause weight gain. Central weight redistribution occurs at menopause as a result of estrogen loss — MHT may actually help counteract this. Some women notice initial bloating when starting, which usually settles.

Herbal and “natural” remedies have not demonstrated meaningful efficacy in rigorous clinical trials for moderate-to-severe symptoms. Some carry safety concerns (black cohosh and liver function; St John’s wort and drug interactions). For mild symptoms or when MHT is not appropriate, evidence-based non-hormonal medications (SSRIs/SNRIs, fezolinetant or elinzanetant, oxybutynin) are more reliably effective.

Menopause does not directly cause dementia. However, estrogen does have brain-protective effects, and there is active research into whether MHT used around the time of menopause may reduce long-term risk. This hasn’t been established with sufficient certainty to prescribe MHT for this purpose. Established risk-reduction strategies include cardiovascular health, physical activity, cognitive engagement, and social connection.

Yes. If your ovaries were removed (bilateral oophorectomy), you have surgical menopause and will experience all the symptoms and health consequences, often more abruptly. If your ovaries were retained, they continue producing hormones until they naturally fail — which may happen somewhat earlier. After hysterectomy, you take estrogen-only MHT (no progestogen needed), which has a more favorable benefit-risk profile.